Executive Highlights
The POD1UM-304 phase 3 trial marks a significant milestone in the management of metastatic non-small-cell lung cancer (NSCLC). The study successfully met its primary endpoint, demonstrating that the addition of retifanlimab, a PD-1 inhibitor, to standard-of-care platinum-based chemotherapy significantly prolongs overall survival (OS) compared to chemotherapy alone.
Key findings include a median OS of 18.1 months in the retifanlimab-chemotherapy group versus 13.4 months in the placebo-chemotherapy group (Hazard Ratio [HR] 0.75; p=0.0042).